


TECHNOLOGY AND KNOWLEDGE TRANSFER

KEYS TO SUCCESSFUL IMPLEMENTATION AND MANAGEMENT



Mark Gibson and Siegfried Schmitt
Editors

www.pda.org/bookstore

CONTENTS

1	INTRODUCTION AND OBJECTIVES	1
	<i>Mark Gibson and Siegfried Schmitt</i>	
	Purpose of the Book	1
	Technology Transfer and the Drug Discovery and Development Process	5
	Why is Technology Transfer Important?	11
	Scope of the Book	13
	References	18
	About the Authors	20
2	TECHNOLOGY TRANSFER AND KNOWLEDGE MANAGEMENT OVER THE DRUG LIFECYCLE	23
	<i>Siegfried Schmitt</i>	
	Introduction	23
	From Data to Knowledge	25
	Transferring or Sharing Data and Knowledge	26
	Knowledge Sharing Standard Operating Procedure (SOP)	31
	Final Conclusions	32
	References	33
	About the Author	33

3 TECHNOLOGY TRANSFER, THE REGULATORY AND BUSINESS PERSPECTIVE	35
<i>Alan Harris and Siegfried Schmitt</i>	
Introduction	35
Regulatory Requirements for Technology Transfer	36
Electronic Records/Electronic Signatures (ER/ES)	42
Safety, Health and Environmental (SHE) Regulations	42
General Safety and Health Considerations	42
Waste Disposal	44
Potential Impact of the Regulations Concerning	
Import/Export of Chemicals	45
Economic Factors	46
New Technology	47
Social Aspects and the Impact on Technology Transfer	50
Language	50
Culture	52
Team Building	52
Conclusions	54
References	55
About the Authors	57
4 TECHNOLOGY TRANSFER ORGANISATION STRATEGY AND PLANNING	59
<i>Steve Burns and Mark Gibson</i>	
Introduction	59
Stages of the Technology Transfer Process	62
Stage 1: pre-technology transfer preparation	63
Stage 2: scale-up and establish process at commercial scale	71
Stage 3: plan and perform process validation	73
Management of Change	76
Organisation	77
Teams Supporting the Technology Transfer Process	80
Global Technology Transfer Management Team (GTTMT)	80
Sending site (R&D) drug substance project team	82
Sending site (R&D) drug product project team	82
Receiving site(s) project teams	85
Documentation Required to Support Technology Transfer	87
Planning	89
Timings	90
References	93
About the Authors	94

5 CHEMICAL DRUG SUBSTANCE DEVELOPMENT AND TECHNOLOGY TRANSFER	97
<i>Alan Harris</i>	
Introduction	97
The Drug Substance Development Process	98
Introduction to drug substance process research and development	98
The role of process R&D	100
Good process design	103
The challenge of discontinuous development	108
Barriers to process changes	110
Introduction to Technology Transfer for Drug Substance	111
Aims of Technology Transfer	113
The Impact of Technology Transfer Issues on Process	
Development Strategies	114
Early development decisions	114
Route selection, regulatory and sourcing strategies	116
Process freeze	117
Potential Impact of REACH Regulations	118
Applying Risk Analysis and Risk Management to Technology	
Transfer Decisions	119
Managing the Technology Transfer Programme	120
Principles for technology transfer	121
The technology transfer team	122
Documentation to be Transferred or Generated During	
Technology Transfer and Establishment of the Process	123
Success Criteria for Technology Transfer	124
Process Validation	125
Case Study 1: Remacemide Hydrochloride	129
Early process evaluation	129
Process R&D work	131
Early technology transfer of the process for DPAP	131
Second source for DPAP	134
Technology transfer of the final stages of the process	135
Salt selection, polymorphism and particle size	136
Lessons from case study 1	136
Case Study 2: Sibenadet Hydrochloride	138
Synthesis and technology transfer of the benzothiazolone amine intermediate	138
Synthesis and technology transfer of the intermediate benzoate ester	141
Technology transfer of the final steps	141
Control of physical form	143

Crystallisation/drying issues	144
Overall lessons from case study 2	145
Case Study 3: Gefitinib (Iressa®)	147
Overall lessons from case study 3	151
Future Directions for Process Development and the Impact on Technology Transfer	152
Microwave and ultrasonic reactors	152
Micro-reactors technology and continuous processes	153
Chromatographic purification techniques	153
Overall Conclusions	154
References	157
About the Author	160

6 **CHEMICAL DRUG PRODUCT DEVELOPMENT AND TECHNOLOGY TRANSFER**

161

<i>Mark Gibson</i>	
Introduction	161
Product Design	168
Product Optimisation	172
Process Design and Optimisation	177
Process Capability and Robustness	182
Use of PAT to Aid Process Optimisation and Understanding	183
Scale-up and Technology Transfer	187
Process Validation	190
Clinical trials process validation	191
Cleaning validation	192
Process validation of the commercial process	
— acceptance by production	194
Post-validation and Post-regulatory Approval Changes	200
Documenting the Drug Development Process	203
Chemical (Small Molecules) Drug Product Technology	
Transfer Case Studies	206
Case study 1: immediate release film coated tablet	206
Case study 2	211
Case study 3: metered dose inhaler	213
References	215
About the Author	218

7 DRUG SUBSTANCE MANUFACTURING PROCESS DEVELOPMENT AND TECHNOLOGY TRANSFERS — BIOPHARMACEUTICALS	219
<i>Lamine Bouakaz</i>	
Introduction	219
Biopharmaceutical Drug Substances	221
Characteristics of biopharmaceutical drug substances	221
Biopharmaceutical vs. chemical manufacture	223
Development Phases for Biopharmaceuticals	226
Pre-clinical program for biopharmaceuticals	226
Clinical trials program for biopharmaceuticals	229
Registration of biopharmaceuticals	230
Commercialization and product lifecycle: Phase IV	231
Development of Biopharmaceutical Drug Substance	
Manufacturing Processes	232
Overview of biopharmaceuticals drug substance manufacturing processes	233
The Quality Target Product Profile	235
Process development for pre-clinical drug substance manufacture	236
Process development for Phase I/II biopharmaceutical drug substance manufacture	240
Phase III biopharmaceutical drug substance manufacturing process development	249
Process and product characterization studies	260
Process validation	263
Registration	266
Knowledge management	268
Biopharmaceutical Drug Substance Manufacturing Process	
Technology Transfer from Development to Commercial Scale	268
Preclinical to Phase I/II manufacturing process technology transfer	269
Phase I/II to Phase III manufacturing process technology transfer	274
Biopharmaceutical Drug Substance Manufacturing	
Process Technology Transfer between Commercial Manufacturing Sites	278
References	284
Abbreviations	286
About the Author	288

8 ANALYTICAL METHODOLOGY AND SPECIFICATIONS	289
<i>Mark Hindle</i>	
Introduction	289
Method transfer scope	291
Analytical technology transfer: what to do before formal transfer starts	292
QC involvement during method validation	295
QC involvement post validation	296
Analytical technology transfer: when does it start and when does it end?	297
Principles of analytical methodology transfer	299
Change control	302
Competition and timing	303
The Technology Transfer Process for Analytical Methodology and Specifications	303
Stages of analytical method transfer	304
Stage 1: Analytical Strategy	306
Analytical method transfer team	306
Analytical transfer strategy document	309
Stage 2: Knowledge and Information Transfer	313
Information package	314
Knowledge transfer	315
Stage 3: Method Transfer Protocol	320
Testing design	322
Use of statistics	328
Approval of method transfer protocol	330
Stage 4: Analytical Testing	331
Stage 5: Summary Report	333
Transfer approval	333
Post transfer monitoring	334
Post approval changes	334
Method transfer — potential problems and how to avoid them	335
Summary	345
References	346
About the Author	348
APPENDIX: SPECIAL CONSIDERATIONS FOR TRANSFER OF BIOASSAY METHODS	349
<i>Sharon Longhurst and Ralf Hess</i>	
Introduction	349
Cell Based Assays	351

Issues for Consideration with Respect to Analytical Transfer Strategy	352
Knowledge and Information Transfer	355
Method Transfer Protocol	356
Ligand Binding Assays	358
Issues for Consideration with Respect to Analytical Transfer	359
<i>In Vivo</i> Assays	359
Issues for Consideration with Respect to Analytical Transfer Strategy	360
Knowledge and Information Transfer	360
Method Transfer Protocol	361
References	361
About the Authors	362
9 TECHNOLOGY TRANSFER, OUTSOURCED ACTIVITIES MANAGEMENT	365
<i>Siegfried Schmitt</i>	
Introduction	365
The purpose of technical/quality agreements	365
What are technical/quality agreements?	366
Quality Agreements	367
Applicable regulations	
Minimum Requirements for Contents	
of a Technical/Quality Agreement	371
Key Performance Indicators for Compliance Through Quality Agreements (PQA, <i>premier-research.com</i>)	375
Challenges to Companies in Developing Quality Agreements	377
Summary	377
Examples	378
References	378
About the Author	379
10 AUDITS AND INSPECTIONS	381
<i>Mark Gibson</i>	
Introduction	381
The PAI Process	385
Common PAI Deficiencies	390
PAI — What will be Inspected?	392
PAI — How to Prepare?	395

Documented PAI policy	395
Formation of PAI preparation team(s)	396
Documentation, data review and retrieval	399
Product development reports	402
Good level of cGMP and compliance	406
Training and awareness	406
PAI and Launch	408
Technology Transfer: Final Conclusions	409
References	411
About the Author	412
II TRAINING, AN ESSENTIAL ELEMENT OF TECHNOLOGY TRANSFER	415
<i>Siegfried Schmitt</i>	
Introduction	415
The Quality by Design Challenge	416
Learning from Technology Transfer	417
Developing a Training Strategy	418
Scope of training	418
Prioritisation and context of training needs	419
Detailed contents of training programmes	420
Methods and tools for delivering training	421
Management of training programmes	422
Trainers	423
Templates and style guidelines	423
Training documentation	424
Language used for training programmes	425
Measuring the Success of Training	425
Auditing of Training	425
Conclusions	426
References	426
About the Author	427
Glossary	429
Index	459